Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HELP Study: Lanadelumab for Long-Term Prophylaxis of Hereditary Angioedema Attacks
2015-003943-20Phase 3Completed
- Sponsor
- Dyax Corp.
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hereditary angioedema (HAE) comparing Lanadelumab prophylaxis with Placebo (2 arms). Primary endpoint: Number of investigator-confirmed HAE attacks. Started Dec 2015; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2015-003943-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003943-20.